Merck and Moderna report first positive Phase 3 result for personalized cancer vaccine
Merck and Moderna announced positive Phase 3 results for intismeran autogene, an mRNA personalized cancer vaccine, combined with Keytruda in melanoma. The trial met recurrence-free and distant metastasis-free survival endpoints. Full data to be presented at a medical meeting; regulatory submissions to begin.
Sentimentbullish +80Strongly bullish
Impact85high · market-wide
Confidence85%Corroborated reports
Eventdeveloping10 wires · v10
The headline is open. The market meaning goes deeper.
Preview the analysis BORSA members receive around every material canonical event.
BORSAPLUSUnlock the intelligence behind the signal.
Create free account · 3 views/day